16 results
S-1/A
EX-1.1
UNCY
Unicycive Therapeutics Inc
7 Jun 21
IPO registration (amended)
7:01am
(including ambient air, surface water, groundwater, land surface or subsurface strata), including laws relating to emissions, discharges, releases
DRS/A
UNCY
Unicycive Therapeutics Inc
2 Nov 20
Draft registration statement (amended)
12:00am
(such as Fosrenol) (see figure below). In addition, it has a lower water solubility at various pH values than the corresponding lanthanum carbonates and also … , resulting in poor adherence to the prescribed drug therapy (Figure 4 below). Lower molecular weight and no water of hydration with Renazorb as compared
DRS/A
UNCY
Unicycive Therapeutics Inc
18 Feb 21
Draft registration statement (amended)
12:00am
exhibited more phosphate binding kinetics than lanthanum carbonates (such as Fosrenol) (see figure below). In addition, it has a lower water solubility … below). Lower molecular weight and no water of hydration with Renazorb as compared with Fosrenol allows Renazorb to be dosed in smaller mass
424B4
UNCY
Unicycive Therapeutics Inc
14 Jul 21
Prospectus supplement with pricing info
1:59pm
figure below). In addition, it has a lower water solubility at various pH values than the corresponding lanthanum carbonates and also produces less carbon … , resulting in poor adherence to the prescribed drug therapy (Figure 4 below). Lower molecular weight and no water of hydration with Renazorb as compared
S-1
khvkz7l
21 May 21
IPO registration
4:07pm
S-1/A
suycwz8 gf5t
7 Jun 21
IPO registration (amended)
7:01am
DRS/A
gw37wvp i3tgn4h8ak
29 Apr 21
Draft registration statement (amended)
12:00am
S-3
1scz8
15 Aug 22
Shelf registration
6:20pm
10-K
z0jecv61my
31 Mar 22
Annual report
6:18am
DRS
q56hx6jbhr6jo0
15 Sep 20
Draft registration statement
12:00am
- Prev
- 1
- Next